The SGLT2 inhibitor dapagliflozin is well tolerated regardless of diabetes status according to new analyzes from the DARE-19 study in adults who were hospitalized...
OPINION: Studies now show that up to 14.4% of people who recover from COVID-19 have been diagnosed with diabetesSince the president Joe BidenApril 28...